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sores), and medication-related risks (liver failure, blood clot). OS was held constant 
at 32 months. Trade-off questions were based on predetermined experimental design 
with known statistical properties. Random-parameters logit model was used to esti-
mate a preference weight for each attribute level. Preference weights were used to 
calculate maximum levels of risks patients were willing to accept for increases in PFS. 
RESULTS: A total of 138 US subjects completed the survey. PFS was the most impor-
tant attribute to patients over the range of levels included in the survey, while remain-
ing attributes were ranked in order of importance as: fatigue, diarrhea, liver failure, 
hand-foot syndrome, blood clot, mouth sores. Increasing PFS by 10 months was as 
important as avoiding severe fatigue and 2-times as important as avoiding severe 
mouth sores. Patients were willing to accept blood-clot risks up to 5.5% (95% CI: 
3.6%–8.6%) and liver-failure risks up to 3.6% (95% CI: 2.6%–4.8%) to increase PFS 
by 10 months. CONCLUSIONS: PFS is a clinical outcome that is important to RCC 
patients. Patients were willing to accept higher treatment-related risks to increase PFS.
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OBJECTIVES: To review PRO labelling claims achieved in antineoplastic products in 
Europe and in the US. METHODS: PROLabels database was searched with neoplasm 
and oncology as keywords to identify antineoplastic agents with PRO labeling claims 
approved or revised in Europe since 1995 and in the US since 1998. FDA and EMEA 
websites and guidances were reviewed. Anti-emetic and analgesic products were not 
included. RESULTS: Among the 101 antineoplastic products approved, 18 were 
identiﬁed with PRO claims—10 in the U.S, 8 in Europe (including one in both agen-
cies)—for 11 different indications: non-small cell lung carcinoma, prostatic neoplasms, 
small cell lung carcinoma, Kaposi sarcoma, chronic myeloid leukemia, astrocytoma, 
pleural malignant mesothelioma, breast neoplasms, head & neck neoplasms, stomach 
neoplasms and colorectal neoplasms. Survival was primary endpoint for 12 products. 
Other primary endpoints included time to progression, response rate and response 
duration. PROs included in labels were primary endpoints in only two cases: one 
product used in prostatic neoplasms (improvement in pain) and one product approved 
for pancreatic neoplasms (clinical beneﬁt response including pain intensity, use of 
rescue medication and performance status). Both products were approved by the FDA. 
Health-related quality of life was clearly mentioned in the label of 7 products (4 
approved by the EMEA including 2 approved after the publication of the EMEA and 
FDA guidances, and 3 by the FDA, all approved before the publication of the guid-
ances). Of these 7 products, 3 approved by the EMEA and 1 by the FDA had an 
indication for non-small cell lung carcinoma. CONCLUSIONS: PROs are rarely used 
as primary endpoints in approval of antineoplastic agents except for assessing pallia-
tive response. When assessed, health-related quality of life is used as a supportive 
endpoint, and more often associated with non-small cell lung carcinoma, especially in 
Europe.
PCN112
LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW FOR THE 
DEVELOPMENT OF A PATIENT-REPORTED OUTCOME RESEARCH 
STRATEGY FOR CANCER-RELATED ANEMIA
Hackshaw MD, Brown J
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: An appraisal of patient-reported outcome (PRO) endpoints and exist-
ing instruments to measure such endpoints was conducted to identify and critically 
review potentially relevant and appropriate instruments for use in clinical trials of 
cancer-related anemia (CRA). The purpose of the study was to determine what PRO 
endpoints and instruments have been used to assess the impact of treatment in reduc-
ing CRA symptoms, and whether the instruments identiﬁed were likely to be of the 
standard acceptable by regulatory authorities to support a label claim. METHODS: 
A systematic search and review of 1486 published scientiﬁc abstracts was conducted 
using MEDLINE and EMBASE, as well as the supporting statements in regulatory 
agency labels for drugs used in the treatment of anemia. Consistency of the identiﬁed 
PRO measures and their psychometric properties with the current Food and Drug 
Administration (FDA) draft guidance on PROs supporting a labeling claim was also 
evaluated. RESULTS: A total of 29 instruments were identiﬁed. Four instruments were 
found to support a label claim or used speciﬁcally in the CRA population (FACT-F, 
FACT-An, CLAS/LASA, EORTC QLQ-C30); these were assessed further. Twenty-ﬁve 
were excluded from further assessment because they were speciﬁc to a particular 
disease other than cancer and covered aspects speciﬁc to these diseases which were 
not relevant to the CRA population. Other exclusion reasons included measurement 
of general health or health-related quality of life (HRQOL) and other symptoms that 
were neither speciﬁc to cancer nor anemia. CONCLUSIONS: None of the four instru-
ments assessed were found to meet all the criteria in the FDA draft guidance; however, 
the ﬁndings help inform the design of new PRO instruments for CRA.
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OBJECTIVES: The purpose of this study was to explore differences among Veterans 
and private-patients on health related quality of life (HRQOL), fear of recurrence 
(FOR), impact of events (IE), illness intrusiveness (IITF) and psychological distress in 
non-muscle invasive bladder cancer (NMIBC) patients and provide direction for 
further study. METHODS: Cross sectional study design was used. Participants were 
drawn from a large private hospital (N = 38) and Veterans Affairs hospital (N = 29) 
in the southeast United States. HRQOL was measured with EORTC-QLQ-C30. FOR 
was measured with 5-item measure used in the Cancer of the Prostate Strategic 
Research Endeavor study. The IE Scale measures subjective response to stress and 
consists of two subscales, intrusive thoughts and avoidance. The IITF measure assesses 
impact of illness on functioning and consists of three subscales, intimacy, instrumental 
life and relationship-personal development. Psychological distress was measured with 
the Brief Symptom Index (BSI), an 18-item measure. Differences among Veterans vs. 
private-patients were assessed with student t-test or chi-square as appropriate. Analy-
ses were performed using the SAS v9.1.3. RESULTS: Majority of respondents were 
older (mean age at diagnosis 65.4(± 8.8) years), white (91.1%), males (83.6%), 
married (70.2%) and largest percentage (35.8%) reported getting some college educa-
tion. Veterans group did not differ from private-patients on age, education, ethnicity, 
relationship status, number of bladder cancer treatments received or time since diag-
nosis (years) (p > 0.05), but differed signiﬁcantly on gender (p = 0.0016). Number of 
comorbidities were also higher in the Veterans group (p = 0.0214). Veterans indicated 
signiﬁcantly higher FOR, psychological distress, illness intrusiveness on intimacy and 
instrumental life, and lower HRQOL compared to private-patients (p < 0.05). CON-
CLUSIONS: Veterans had higher level of FOR and psychological distress but lower 
HRQOL, than private-patients. Interventions to manage patients’ fear of recurrence, 
psychological distress and help them adapt to altered routine may assist NMIBC 
patients.
PCN114
EXPLORING THE BURDEN OF ILLNESS ON NEWLY DIAGNOSED 
ESOPHAGEAL CANCER PATIENTS IN TAIWAN –PRELIMINARY 
ANALYSIS
Lin HW, Ku CH, Lee RF, Shih TP, Liu YY, Lin CY
China Medical University, Taichung, Taiwan
OBJECTIVES: Esophageal cancer (EC) is the seventh cancer among male patients in 
Taiwan. Difﬁculty swallowing makes EC patients vulnerable to nutritional challenges 
and impacts their treatment outcomes and well-being. The aims of this study are to 
explore the EC patients’ burden of illness on nutritional and well-being aspects. 
METHODS: A longitudinal observation study is conducting to recruit newly diag-
nosed EC patients from the CMU Hospital in Taichung, Taiwan since June 2009. 
Fresh EC patients were assessed before (T0) and after receiving any main treatments 
(T1 [1-month], T2 [3-month], T3 [6-month] after treatment(s)) if it is not impossible. 
Well trained interviewers solicited patients’ responses on 1) Nutritional Risk Screen 
(NRS-2002); 2) Chinese versions of EQ-5D and FACT-E. The descriptive analyses 
were performed to examine the trends among different stages of EC patients. 
RESULTS: Up to the date of analysis(December 31, 2009), of 27 recruited EC patients, 
average age was 53 ± 9 years-old and more than 90% were diagnosed with squamous 
cell carcinoma (³85% with clinical stage at III and above). There were 23, 14, 5 and 
2 patients completed the T0, T1, T2 and T3 assessments, respectively. Approximately 
70% and 80% of patients at T0 and T2 had NR-2002S scored greater than 3 (with 
deﬁned risk of malnutrition). From T0 to T3, upon the solicited, completed responses, 
patients seemed to be deteriorated on the daily activities and social well-being (i.e., 
self-care, usual activity of EQ-5D, and physical and social well-being of FACT-E) but 
improve on esophageal cancer related symptoms and signs (additional concerns of EC) 
after treatments. CONCLUSIONS: This preliminary analysis showed the extent of EC 
patients’ burden of illness and its change over time. Further assessments are necessary 
to facilitate the decision making about appropriate management of EC patients on the 
aspect of nutrition and health-related quality of life.
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OBJECTIVES: Although several health-related quality of life (HRQOL) instruments 
exist for adult cancer survivors, little attention has been paid to identify appropriate 
instruments for young adult survivors of childhood and adolescent cancer (YASCAC). 
We aim to make head-to-head comparisons of 3 HRQOL instruments for YASCAC. 
METHODS: We collected data via telephone interviews between 05/01/2009 and 
09/30/2009 from 141 YASCAC who were off therapy at least 2 years without cancer 
and enrolled in the CSP and/or the UF Tumor Registry. Each subject reported his/her 
late effects (yes/no) and HRQOL. HRQOL was measured using the Quality of Life 
